Status:
TERMINATED
OPSCC N0 Nodal Control With Reduced IMRT
Lead Sponsor:
Paul W. Read, MD
Conditions:
Oropharyngeal Squamous Cell Carcinoma (OPSCCA)
HPV (Human Papillomavirus)-Associated
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The dose of radiation most commonly used to treat oropharyngeal cancer results in side effects including sores in the mouth and throat, dry mouth and thick saliva, loss or altered taste, swallowing pr...
Detailed Description
A Pilot Single Arm Study of Intensity Modulated Radiation Therapy Elective Nodal Dose De-Escalation for HPV-Associated Squamous Cell Carcinoma of the Oropharynx.
Eligibility Criteria
Inclusion
- patient must be clinically referred for radiation for stage I-IVb OPSCCA
- tumor must be HPV-associated p16+
- patient must be able to lie flat and tolerate immobilization systems
Exclusion
- patients may not be receiving any investigational agents
- prior radiation to head and neck
- any other malignancy except non-melanomatous skin cancer or a carcinoma not of head and neck origin with patient being disease free for at least 5 years
- any major medical, psychiatric, or neurologic illness
- pregnant or breastfeeding women
Key Trial Info
Start Date :
October 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01891695
Start Date
October 1 2013
End Date
December 1 2016
Last Update
October 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Virginia Health System
Charlottesville, Virginia, United States, 22908